Is MPLT or IFRX more profitable?

Maplight Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A InflaRx N/A -53.56% -43.02%

Does the media refer more to MPLT or IFRX?

In the previous week, InflaRx had 10 more articles in the media than Maplight Therapeutics. MarketBeat recorded 15 mentions for InflaRx and 5 mentions for Maplight Therapeutics. InflaRx's average media sentiment score of 0.64 beat Maplight Therapeutics' score of 0.55 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMMX or IFRX more profitable?

InflaRx's return on equity of -53.56% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -64.24% -54.25% InflaRx N/A -53.56% -43.02%

Does the media refer more to IMMX or IFRX?

In the previous week, InflaRx had 4 more articles in the media than Immix Biopharma. MarketBeat recorded 15 mentions for InflaRx and 11 mentions for Immix Biopharma. InflaRx's average media sentiment score of 0.64 beat Immix Biopharma's score of -0.07 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral InflaRx 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, IFRX or AGMB?

InflaRx has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 4,722.95 -$51.63M -$0.58 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Is IFRX or AGMB more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% AgomAb Therapeutics N/A N/A N/A

Does the media favor IFRX or AGMB?

In the previous week, InflaRx had 13 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 15 mentions for InflaRx and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.69 beat InflaRx's score of 0.64 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IFRX or EIKN more profitable?

Eikon Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Eikon Therapeutics N/A N/A N/A

Does the media prefer IFRX or EIKN?

In the previous week, InflaRx had 12 more articles in the media than Eikon Therapeutics. MarketBeat recorded 15 mentions for InflaRx and 3 mentions for Eikon Therapeutics. InflaRx's average media sentiment score of 0.64 beat Eikon Therapeutics' score of 0.34 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eikon Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, IFRX or EVMN?

InflaRx has higher earnings, but lower revenue than Evommune. InflaRx is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 4,722.95 -$51.63M -$0.58 N/A Evommune $13M 39.17 -$68.87M -$11.03 N/A

Is IFRX or EVMN more profitable?

InflaRx's return on equity of -53.56% beat Evommune's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Evommune N/A -62.63% -40.55%

Does the media refer more to IFRX or EVMN?

In the previous week, InflaRx had 5 more articles in the media than Evommune. MarketBeat recorded 15 mentions for InflaRx and 10 mentions for Evommune. InflaRx's average media sentiment score of 0.64 beat Evommune's score of 0.07 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

InflaRx (IFRX) Competitors

$1.96 +0.12 (+6.52%)

As of 08/10/2026 04:00 PM Eastern

Compare

IFRX vs. MPLT, IMMX, AGMB, EIKN, and EVMN

Should you buy InflaRx stock or one of its competitors? InflaRx's main competitors and comparable companies include Maplight Therapeutics (MPLT), Immix Biopharma (IMMX), AgomAb Therapeutics (AGMB), Eikon Therapeutics (EIKN), and Evommune (EVMN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does InflaRx compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

InflaRx has higher revenue and earnings than Maplight Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
InflaRx	$30K	4,722.95	-$51.63M	-$0.58	N/A

Maplight Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
InflaRx	N/A	-53.56%	-43.02%

Maplight Therapeutics currently has a consensus price target of $31.17, indicating a potential upside of 155.88%. InflaRx has a consensus price target of $7.33, indicating a potential upside of 274.15%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

42.4% of InflaRx shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, InflaRx had 10 more articles in the media than Maplight Therapeutics. MarketBeat recorded 15 mentions for InflaRx and 5 mentions for Maplight Therapeutics. InflaRx's average media sentiment score of 0.64 beat Maplight Therapeutics' score of 0.55 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InflaRx	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InflaRx beats Maplight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does InflaRx compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Immix Biopharma has higher earnings, but lower revenue than InflaRx. Immix Biopharma is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
InflaRx	$30K	4,722.95	-$51.63M	-$0.58	N/A

Immix Biopharma has a beta of 0.11, meaning that its share price is 89% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

In the previous week, InflaRx had 4 more articles in the media than Immix Biopharma. MarketBeat recorded 15 mentions for InflaRx and 11 mentions for Immix Biopharma. InflaRx's average media sentiment score of 0.64 beat Immix Biopharma's score of -0.07 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
InflaRx	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immix Biopharma presently has a consensus target price of $21.43, indicating a potential upside of 111.54%. InflaRx has a consensus target price of $7.33, indicating a potential upside of 274.15%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

InflaRx's return on equity of -53.56% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-64.24%	-54.25%
InflaRx	N/A	-53.56%	-43.02%

Summary

InflaRx beats Immix Biopharma on 12 of the 15 factors compared between the two stocks.

How does InflaRx compare to AgomAb Therapeutics?

InflaRx (NASDAQ:IFRX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, InflaRx had 13 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 15 mentions for InflaRx and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.69 beat InflaRx's score of 0.64 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AgomAb Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
AgomAb Therapeutics	N/A	N/A	N/A

InflaRx has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,722.95	-$51.63M	-$0.58	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

InflaRx presently has a consensus price target of $7.33, indicating a potential upside of 274.15%. AgomAb Therapeutics has a consensus price target of $33.00, indicating a potential upside of 120.00%. Given InflaRx's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than AgomAb Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

InflaRx beats AgomAb Therapeutics on 8 of the 12 factors compared between the two stocks.

How does InflaRx compare to Eikon Therapeutics?

InflaRx (NASDAQ:IFRX) and Eikon Therapeutics (NASDAQ:EIKN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

In the previous week, InflaRx had 12 more articles in the media than Eikon Therapeutics. MarketBeat recorded 15 mentions for InflaRx and 3 mentions for Eikon Therapeutics. InflaRx's average media sentiment score of 0.64 beat Eikon Therapeutics' score of 0.34 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eikon Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eikon Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Eikon Therapeutics	N/A	N/A	N/A

InflaRx currently has a consensus target price of $7.33, indicating a potential upside of 274.15%. Eikon Therapeutics has a consensus target price of $25.20, indicating a potential upside of 158.99%. Given InflaRx's stronger consensus rating and higher probable upside, equities analysts plainly believe InflaRx is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

InflaRx has higher revenue and earnings than Eikon Therapeutics. Eikon Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,722.95	-$51.63M	-$0.58	N/A
Eikon Therapeutics	N/A	N/A	-$324.25M	-$2.46	N/A

Summary

InflaRx beats Eikon Therapeutics on 11 of the 14 factors compared between the two stocks.

How does InflaRx compare to Evommune?

InflaRx (NASDAQ:IFRX) and Evommune (NYSE:EVMN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

InflaRx has higher earnings, but lower revenue than Evommune. InflaRx is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,722.95	-$51.63M	-$0.58	N/A
Evommune	$13M	39.17	-$68.87M	-$11.03	N/A

InflaRx's return on equity of -53.56% beat Evommune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Evommune	N/A	-62.63%	-40.55%

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 31.1% of Evommune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

InflaRx currently has a consensus target price of $7.33, indicating a potential upside of 274.15%. Evommune has a consensus target price of $43.25, indicating a potential upside of 208.27%. Given InflaRx's stronger consensus rating and higher possible upside, equities analysts clearly believe InflaRx is more favorable than Evommune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Evommune	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

In the previous week, InflaRx had 5 more articles in the media than Evommune. MarketBeat recorded 15 mentions for InflaRx and 10 mentions for Evommune. InflaRx's average media sentiment score of 0.64 beat Evommune's score of 0.07 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InflaRx beats Evommune on 9 of the 14 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$133.02M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-3.38	9.09	269.19	24.72
Price / Sales	4,722.95	1,255.18	588.76	97.80
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	3.02	17.66	11.27	6.42
Net Income	-$51.63M	-$13.25M	$3.45B	$347.03M
7 Day Performance	10.11%	3.11%	1.92%	0.69%
1 Month Performance	-4.39%	-1.68%	-0.58%	-0.90%
1 Year Performance	138.15%	61.75%	75.49%	21.87%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.6653 of 5 stars	$1.96 +6.5%	$7.33 +274.1%	+144.9%	$133.02M	$30K	N/A	60	News Coverage Earnings Report Analyst Revision
MPLT Maplight Therapeutics	3.3985 of 5 stars	$12.18 -8.3%	$34.42 +182.6%	N/A	$519.33M	N/A	N/A	109	Analyst Downgrade
IMMX Immix Biopharma	2.7454 of 5 stars	$9.47 -5.9%	$20.71 +118.7%	+323.8%	$515.26M	N/A	N/A	9	Earnings Report Upcoming Earnings Analyst Forecast
AGMB AgomAb Therapeutics	2.6314 of 5 stars	$14.11 +4.5%	$33.00 +133.8%	N/A	$511.45M	N/A	N/A	62	Positive News Earnings Report High Trading Volume
EIKN Eikon Therapeutics	2.8134 of 5 stars	$9.43 +2.4%	$25.20 +167.2%	N/A	$510.54M	N/A	N/A	384	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors

IFRX vs. MPLT, IMMX, AGMB, EIKN, and EVMN

How does InflaRx compare to Maplight Therapeutics?

Summary

How does InflaRx compare to Immix Biopharma?

Summary

How does InflaRx compare to AgomAb Therapeutics?

Summary

How does InflaRx compare to Eikon Therapeutics?

Summary

How does InflaRx compare to Evommune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InflaRx (IFRX) Competitors

IFRX vs. MPLT, IMMX, AGMB, EIKN, and EVMN

How does InflaRx compare to Maplight Therapeutics?

Which has better earnings & valuation, MPLT or IFRX?

Is MPLT or IFRX more profitable?

Do analysts prefer MPLT or IFRX?

Do insiders & institutionals have more ownership in MPLT or IFRX?

Does the media refer more to MPLT or IFRX?

Summary

How does InflaRx compare to Immix Biopharma?

Which has higher valuation & earnings, IMMX or IFRX?

Which has more risk and volatility, IMMX or IFRX?

Does the media refer more to IMMX or IFRX?

Do insiders and institutionals hold more shares of IMMX or IFRX?

Do analysts prefer IMMX or IFRX?

Is IMMX or IFRX more profitable?

Summary

How does InflaRx compare to AgomAb Therapeutics?

Does the media favor IFRX or AGMB?

Do insiders & institutionals have more ownership in IFRX or AGMB?

Is IFRX or AGMB more profitable?

Which has higher earnings and valuation, IFRX or AGMB?

Do analysts prefer IFRX or AGMB?

Summary

How does InflaRx compare to Eikon Therapeutics?

Does the media prefer IFRX or EIKN?

Do institutionals and insiders have more ownership in IFRX or EIKN?

Is IFRX or EIKN more profitable?

Do analysts prefer IFRX or EIKN?

Which has preferable valuation and earnings, IFRX or EIKN?

Summary

How does InflaRx compare to Evommune?

Which has preferable earnings and valuation, IFRX or EVMN?

Is IFRX or EVMN more profitable?

Do institutionals & insiders have more ownership in IFRX or EVMN?

Do analysts recommend IFRX or EVMN?

Does the media refer more to IFRX or EVMN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IFRX vs. The Competition

InflaRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools